JP2002212090A - Antibacterial agent for methicillin-resistant staphylococcus aureus - Google Patents

Antibacterial agent for methicillin-resistant staphylococcus aureus

Info

Publication number
JP2002212090A
JP2002212090A JP2001347387A JP2001347387A JP2002212090A JP 2002212090 A JP2002212090 A JP 2002212090A JP 2001347387 A JP2001347387 A JP 2001347387A JP 2001347387 A JP2001347387 A JP 2001347387A JP 2002212090 A JP2002212090 A JP 2002212090A
Authority
JP
Japan
Prior art keywords
tea
oolong
mrsa
staphylococcus aureus
antibacterial agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001347387A
Other languages
Japanese (ja)
Other versions
JP3746705B2 (en
Inventor
Hiroshi Fujiwara
弘 藤原
Takeshi Sawai
健 澤井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TOYO PHARMA KK
Toyo Seiyaku Kasei Co Ltd
Original Assignee
TOYO PHARMA KK
Toyo Seiyaku Kasei Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TOYO PHARMA KK, Toyo Seiyaku Kasei Co Ltd filed Critical TOYO PHARMA KK
Priority to JP2001347387A priority Critical patent/JP3746705B2/en
Publication of JP2002212090A publication Critical patent/JP2002212090A/en
Application granted granted Critical
Publication of JP3746705B2 publication Critical patent/JP3746705B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide an antibacterial agent which exhibits an extremely remarkable antibacterial activity against staphylococcus, especially Methicillin-resistant Staphylococcus aureus. SOLUTION: This antibacterial agent contains a hot water extract obtained by extracting the leaves and/or stems of SENRINKEI alpine tea and/or HAKUGO oolong tea produced in Taiwan as an active ingredient.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、ヒト及び家畜,ペ
ット等に対して病原性を有するブドウ球菌(Staphyloco
ccus属)のうち、院内感染の病因菌として問題となって
いるメチシリン耐性黄色ブドウ球菌(methicillin resi
stant Staphylococcus aureus、以下MRSAという)
に対して抗菌作用を発揮する抗菌剤に関するものであ
る。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a staphylococcus (Staphyloco
ccus sp.), a methicillin-resistant Staphylococcus aureus (methicillin resi
stant Staphylococcus aureus (hereinafter referred to as MRSA)
The present invention relates to an antibacterial agent which exerts an antibacterial action on the antibacterial agent.

【0002】[0002]

【従来の技術】ブドウ球菌は、ヒト及び動物における各
種炎症、例えば皮膚化膿症,結膜炎,副鼻腔炎,中耳
炎,膀胱炎,肺炎,骨髄炎,関節炎,内臓膿瘍の起炎菌
として知られている。中でも黄色ブドウ球菌(Staphylo
coccus aureus)はヒト及び動物の化膿症の重要な原因
菌であり、その産生する腸管毒エンテロトキシンにより
食中毒の原因菌ともなるものである。近年では特に、多
種類の抗生物質に対して耐性を示すMRSAによる院内
感染または菌交代症による重篤な腸炎が問題となってい
る。
BACKGROUND OF THE INVENTION Staphylococci are known as pathogenic bacteria of various inflammations in humans and animals, such as dermatitis, conjunctivitis, sinusitis, otitis media, cystitis, pneumonia, osteomyelitis, arthritis and visceral abscess. . In particular, Staphylo
coccus aureus) is an important causative agent of purulence in humans and animals, and also a causative agent of food poisoning due to enterotoxin enterotoxin produced by it. In recent years, in particular, serious enteritis due to nosocomial infection or bacterial alternation due to MRSA showing resistance to various antibiotics has become a problem.

【0003】MRSAはその名の通り、抗生物質メチシ
リンに耐性のある黄色ブドウ球菌である。即ち、黄色ブ
ドウ球菌に対し、強力な抗菌作用を有するメチシリン骨
格の薬剤(例えばペニシリン系やセファロスポリン系薬
剤等)に対し、耐性を獲得したのがMRSAである。
[0003] As the name implies, MRSA is Staphylococcus aureus resistant to the antibiotic methicillin. That is, MRSA has acquired resistance to a methicillin-based drug (for example, penicillin or cephalosporin drug) having a strong antibacterial action against Staphylococcus aureus.

【0004】MRSAは、全てのペニシリン系薬剤;第
一、第二、第三世代と呼ばれる全てのセフェム系薬剤;
モノバクタム系薬剤;カルバペネム系薬剤等、市販され
ている全てのβ-ラクタム薬に対して広範な薬剤耐性を
発揮する。更に、ニューキノロン系薬剤にも耐性を示す
ことが知られている。最近では、MRSAによる感染症
の治療目的で使用されていたバンコマイシンにも耐性の
菌が出現したことが報告される等、MRSAに有効な抗
菌剤の提供が益々切望されている。
[0004] MRSA is all penicillins; all cephem drugs called first, second and third generation;
Monobactams: Exhibit a wide range of drug resistance to all commercially available β-lactam drugs such as carbapenems. Furthermore, it is known that it also exhibits resistance to new quinolones. Recently, it has been reported that vancomycin, which has been used for the treatment of infections caused by MRSA, has also appeared to be resistant to MRSA. For example, it has been increasingly desired to provide an antibacterial agent effective for MRSA.

【0005】更にMRSAは、多剤耐性を示すのみなら
ず、病原性が極めて強く発現される場合がある。特に感
染に対して抵抗力の弱くなった易感染患者へのMRSA
感染が深刻な問題となっている。例えば白血病や癌等で
免疫不全状態に陥った患者、高度熱傷患者、寝たきり老
人や未熟児等の重篤患者がMRSAに感染したときに
は、治癒が極めて困難であるのが実情である。
[0005] Furthermore, MRSA not only shows multidrug resistance, but also may exhibit extremely strong pathogenicity. MRSA especially for compromised patients with reduced resistance to infection
Infection is a serious problem. For example, it is extremely difficult to cure MRSA when serious patients such as patients suffering from immunodeficiency due to leukemia or cancer, severely burned patients, bedridden elderly people and premature babies are infected with MRSA.

【0006】[0006]

【発明が解決しようとする課題】本発明は上記事情に着
目してなされたものであり、その目的は、MRSAに対
して有効な抗菌作用を発揮する抗菌剤を提供することに
ある。
SUMMARY OF THE INVENTION The present invention has been made in view of the above circumstances, and an object of the present invention is to provide an antibacterial agent which exhibits an effective antibacterial action against MRSA.

【0007】[0007]

【課題を解決するための手段】上記課題を達成し得た本
発明のメチシリン耐性黄色ブドウ球菌抗菌剤は、有効成
分として、台湾原産の杉林渓高山茶及び/又は白豪烏龍
の茶葉及び/又は茎から抽出される熱水抽出物を含有す
るところに要旨を有するものである。
The methicillin-resistant Staphylococcus aureus antibacterial agent of the present invention, which has achieved the above objects, has, as an active ingredient, Suginrinkei Takayama tea native to Taiwan and / or tea leaves and / or white oolong oolong tea. Alternatively, it has a gist in containing a hot water extract extracted from a stem.

【0008】[0008]

【発明の実施の形態】本発明者らは、ブドウ球菌、とり
わけMRSAに対して有効な抗菌作用を発揮し得る抗菌
剤を提供すべく、特に茶に着目して鋭意検討してきた。
具体的には、日本原産の茶葉35種、台湾原産の茶葉1
5種、中国原産の茶葉5種を用い、MRSAを含め種々
のブドウ球菌に対する抗菌作用を詳細に調べた。その結
果、台湾原産の杉林渓高山茶及び白豪烏龍の二種類の茶
葉及び/又は茎が、ブドウ球菌、なかでもMRSAの生
育を極めて有効に阻止し得ることを見出し、本発明を完
成した。
BEST MODE FOR CARRYING OUT THE INVENTION The present inventors have studied diligently with a particular focus on tea in order to provide an antibacterial agent capable of exhibiting an effective antibacterial action against staphylococci, especially MRSA.
Specifically, 35 tea leaves native to Japan, 1 tea leaf native to Taiwan
Using five kinds of tea leaves and five kinds of tea leaves native to China, the antibacterial activity against various staphylococci including MRSA was examined in detail. As a result, they have found that two types of tea leaves and / or stems of Suginrinkei Takayama tea and white oolong, native to Taiwan, can extremely effectively inhibit the growth of staphylococci, especially MRSA, and completed the present invention. .

【0009】一般に茶は、ツバキ科に属する茶樹の若芽
(葉)を採取して調製されたものであり、製法により、
不発酵茶(緑茶)、半発酵茶(ウーロン茶等)、発酵茶
(紅茶)に大別される。更に、製法や原料の種類、形等
によって、例えば半発酵茶は烏龍茶と包種茶に大別され
る。
[0009] In general, tea is prepared by collecting young shoots (leaves) of tea plant belonging to the family Camellia.
It is roughly classified into unfermented tea (green tea), semi-fermented tea (oolong tea, etc.), and fermented tea (black tea). Furthermore, for example, semi-fermented tea is roughly classified into oolong tea and wrapping tea according to the production method, the type and shape of the raw materials, and the like.

【0010】茶は、その優雅な香りと味のため、嗜好飲
料として好まれるのみならず、様々な生理作用を有する
ことが知られている。例えば茶葉中に大量に含まれるカ
テキン(タンニン)は、抗癌作用や老化防止作用、血中
コレステロール濃度の低下作用等を有することが知られ
ている。
[0010] Because of its elegant aroma and taste, tea is known not only to be a favorite beverage but also to have various physiological effects. For example, it is known that catechin (tannin) contained in tea leaves in a large amount has an anticancer effect, an antiaging effect, a blood cholesterol lowering effect, and the like.

【0011】最近の研究によれば、茶の中に含まれるカ
テキンの有用性が盛んにアピールされ、例えば、ある日
本茶の浸出液は、猛毒性の病原性大腸菌O157を殺菌
し、ベロ毒素も解毒する作用があるなどの報告がされて
いる。本発明者らもカテキンに着目し、ブドウ球菌、特
にMRSAに対する抗菌作用があるのではないかと検討
してみたが、濃度の高いカテキン単味では、所望の抗菌
効果は得られないことが分かった。
According to recent studies, the usefulness of catechins contained in tea has been actively promoted. For example, a Japanese tea leaching solution can kill highly virulent pathogenic Escherichia coli O157 and detoxify toxin. It has been reported that it has an action to do. The present inventors have also paid attention to catechin and examined whether it has an antibacterial action against staphylococci, particularly MRSA, but found that a high concentration of catechin alone does not provide a desired antibacterial effect. .

【0012】更にカテキンの含有量に留意しつつ、種々
の茶を検討してみたが、カテキンとブドウ球菌抗菌作用
の間に有為な相関関係は認められなかった。例えば日本
の緑茶は、比較的低温度の湯を注いで飲用するので、苦
味成分であるカテキン等は茶の中に比較的多量に溶出す
る。また、焙茶は、煎茶を焙煎したものであるが、焙煎
によってカテキン類が減少してしまう。更に、烏龍茶、
包種茶の半発酵茶は、沸騰した熱湯を注ぎ、3〜5分蒸
らしてから飲用するため、カテキン類は緑茶の半分以下
に減少する。この様にカテキン類含有量の異なる種々の
茶についてMRSAに対する抗菌作用を調べてみたとこ
ろ、前述の如くカテキン量が少ないと考えられている烏
龍茶であっても、台湾産の白豪烏龍の茶葉を飲用する
と、優れた抗菌作用が得られることが分かった。これに
対し、台湾産の凍頂烏龍では、MRSAに対する抗菌作
用は得られなかった。一方、台湾産の杉林渓高山茶は烏
龍茶として使用されるが、これも上記白豪烏龍と同様、
優れた抗菌作用を示すことが分かった。従って、本発明
による抗菌作用は、必ずしもカテキンだけの作用による
ものではないことが伺える。
Further, various teas were examined while paying attention to the content of catechin, but no significant correlation was found between catechin and staphylococcal antibacterial activity. For example, Japanese green tea is drunk by pouring relatively low-temperature hot water, so that a relatively large amount of catechin or the like, which is a bitter component, elutes in the tea. Roasted tea is roasted sencha, but roasting reduces catechins. In addition, oolong tea,
Semi-fermented tea of wrapping tea is poured after boiling boiling water and steamed for 3 to 5 minutes, so that catechins are reduced to less than half of green tea. When the antibacterial activity against MRSA of various teas having different catechin contents was examined as described above, even if the oolong tea was considered to have a small amount of catechin as described above, the tea leaves of the white Australian oolong from Taiwan. It was found that when drinking, excellent antibacterial action was obtained. On the other hand, the antifreeze effect against MRSA was not obtained in the frozen oolong from Taiwan. On the other hand, Suginrinkei Takayama tea from Taiwan is used as oolong tea, but this is also the same as the above-mentioned white oolong oolong,
It was found to show excellent antibacterial action. Therefore, it can be seen that the antibacterial action according to the present invention is not necessarily due to the action of catechin alone.

【0013】ちなみに本発明に用いる2種の茶葉につ
き、カテキン量を調べたところ、非常に少ないか殆ど検
出することができなかった。例えば白豪烏龍の場合、こ
の茶葉及び/又は茎15gを90℃の水650mLに浸
した後、室温で30秒間放置し、濾過した濾液中のカテ
キン量を、FOLIN−DENIS法により測定したと
ころ、カテキン(タンニン酸として検出される)は検出
されなかった(検出限界0.01g/100g)。一
方、杉林渓高山茶についても同様の方法で測定したとこ
ろ、タンニン酸として僅かに0.03g/100g検出
されたに過ぎなかった。
By the way, when the amount of catechin was examined for the two kinds of tea leaves used in the present invention, it was found that the amount was very small or hardly detectable. For example, in the case of the white oolong, 15 g of this tea leaf and / or stem was immersed in 650 mL of water at 90 ° C., left at room temperature for 30 seconds, and the amount of catechin in the filtered filtrate was measured by the FOLIN-DENIS method. And catechin (detected as tannic acid) were not detected (detection limit: 0.01 g / 100 g). On the other hand, the measurement of Sugibayashi Takayama tea by the same method revealed that only 0.03 g / 100 g of tannic acid was detected.

【0014】本発明に用いた上記の台湾産の茶葉が何
故、MRSAに対し、極めて優れた抗菌作用を発揮し得
るのかは詳細には不明であるが、少なくとも上記基礎実
験から、従来より茶葉中の薬効成分と考えられていたカ
テキン単独では、MRSAを始めとするブドウ球菌抗菌
作用は認められないことを考慮すれば、台湾の土壌や気
候、栽培条件、茶葉中の有効成分等が複雑に絡み合って
所望の抗菌作用を示したものと思料される。
It is unknown in detail why the above-mentioned Taiwanese tea leaves used in the present invention can exert an extremely excellent antibacterial action against MRSA. Considering that catechin alone, which was considered to be a medicinal component of catechin, does not show any antibacterial activity against staphylococci such as MRSA, Taiwan's soil, climate, cultivation conditions, and active ingredients in tea leaves are intricately intertwined. Thus, it is considered that the desired antibacterial action was exhibited.

【0015】ここで、本発明に用いられる茶について説
明する。
Here, the tea used in the present invention will be described.

【0016】まず、白豪烏龍は、台湾でしか生産されて
いない[製造元:新華茶行(有)]発酵度が約60〜7
0%の青茶(烏龍茶)であり、紅茶に近いタイプの烏龍
茶として知られている。半発酵茶のうち茶芽より製造し
たものは白豪烏龍しかなく、通常の半発酵茶に比べ、発
酵度が高いという特徴がある。上記茶芽は、心芽が肥大
なものが好ましく、主に青心大有、台茶17号、白毛猴
等の茶樹が用いられる。主な産地は、台湾の新竹北埔、
苗栗、頭分等である。上記白豪烏龍を調製するに当たっ
ては、まず、茶葉及び/又は茎を長時間弱い陽射しに曝
し、茶芽がやや白くなるまで萎縮して茎の表皮が皺状に
縮んだ時点で室内に移行し、香りが出るまで撹拌する。
次いで、得られた茶芽を低温で炒め、濡らした布で覆っ
た後、粉々にならない程度に揉んでから、約90℃の熱
風で乾燥することにより得られる。
First, white oolong is produced only in Taiwan [Manufacturer: Xinhua Tea Co., Ltd.] The fermentation degree is about 60-7.
It is 0% blue tea (oolong tea), and is known as a type of oolong tea similar to black tea. Of the semi-fermented teas, the only one produced from tea buds is the white oolong dragon, which is characterized by a higher degree of fermentation than ordinary semi-fermented tea. The tea buds preferably have an enlarged heart bud, and tea trees such as Aishin Taiyu, Taicha No. 17, and white hair monkey are mainly used. Main production area is Hsinchu Beipu in Taiwan,
Miaoli, head, etc. In preparing the above white oolong, first, the tea leaves and / or stems are exposed to weak sunlight for a long time, and when the tea buds are slightly whitened and the epidermis of the stems shrink in a wrinkle-like manner, the tea leaves and indoors are transferred to the room. Stir until scent appears.
Next, the obtained tea buds are roasted at a low temperature, covered with a wet cloth, rubbed so as not to shatter, and then dried with hot air at about 90 ° C.

【0017】また、杉林渓高山茶は、台湾中央山脈の杉
林渓(主な産地は、嘉義縣、南投縣等)で栽培されてい
る発酵度約15〜30%の青茶(烏龍茶)であり、主に
半球型烏龍(例えば青心烏龍)の茶樹が用いられる。高
山栽培による影響で茶葉の色は青緑色を呈しており、苦
味や渋みは殆ど無く、喉に香りがいつまでも残る余韻を
呈する良質な香茶として知られている。製造方法は通常
の烏龍茶と同じであり、弱い陽射しに曝した後、室内に
移して撹拌し、発酵させた後、炒茶、加熱、揉捻、乾燥
の各工程を経て得られる。具体的には、新華茶行(有)
で製造されたものを用いればよい。
[0017] Suginrinkei Takayama tea is a green tea (oolong tea) having a fermentation degree of about 15 to 30%, which is cultivated in Suginrinkei in the Central Taiwan Mountains (main production areas are Chiayi County, Nantou County, etc.). Hemisphere type oolong (eg, blue heart oolong) tea tree is mainly used. The tea leaves have a bluish-green color due to the effects of alpine cultivation, have little bitterness or astringency, and are known as good-quality incense tea with a lingering scent that lasts forever. The production method is the same as that of ordinary oolong tea. After being exposed to weak sunlight, it is moved into a room, stirred and fermented, and then obtained through roasted tea, heating, kneading, and drying. Specifically, Xinhua tea line (Yes)
May be used.

【0018】本発明の抗菌剤は、有効成分として、上記
の茶葉及び/又は茎の熱水抽出物を含有するものであ
る。所望の抗菌効果を得る為には、上記熱水抽出物の濃
度を、概ね、約2〜15%、好ましくは2〜10%に調
整することが推奨される。後記する実施例からも明らか
な通り、上記熱水抽出物の濃度を高くすればする程、抗
菌作用も上昇する傾向にあるが、服用のし易さ等とのバ
ランスも考慮すれば、通常は、約2〜10gの茶葉に対
し、約100ccのお湯を注いで調整することが推奨さ
れる。例えば茶パックとして使用する場合、1パック当
たり2.5gずつ若しくは5.0gずつ詰め、これに6
5〜95℃のお湯を約100cc注いで服用することが
好ましい。この様な濃度に調整した熱水抽出物は、1回
当たり、約1.2〜2.0cc/kgを、一日3〜4回
服用することが推奨される。
The antibacterial agent of the present invention contains the above-mentioned hot water extract of tea leaves and / or stem as an active ingredient. In order to obtain a desired antibacterial effect, it is recommended to adjust the concentration of the hot water extract to about 2 to 15%, preferably 2 to 10%. As is clear from the examples described later, the higher the concentration of the hot water extract, the higher the antibacterial effect tends to increase.However, taking into account the balance with ease of taking, etc., usually, It is recommended to pour about 100 cc of hot water for about 2 to 10 g of tea leaves. For example, when used as a tea pack, pack 2.5 g or 5.0 g per pack, and add 6 g
It is preferable to pour about 100 cc of hot water at 5 to 95 ° C. for taking. It is recommended to take about 1.2 to 2.0 cc / kg of the hot water extract adjusted to such a concentration at a time, 3 to 4 times a day.

【0019】本発明では、上述した台湾産の杉林渓高山
茶及び白豪烏龍の茶葉及び/又は茎の熱水抽出物を、夫
々、単独で使用しても良いし、2種を併用しても構わな
い。両者を併用するときには、合計含有量が上記範囲に
なる様、概ね等量ずつ使用することが好ましい。勿論、
この量に制限する趣旨では決してなく、所望の抗菌作用
が得られる範囲で、被験者の状態、性別、体重等に応じ
て、含有量を適切に調整することができる。
In the present invention, the above-mentioned hot water extract of the tea leaves and / or stems of Sugirinkei Takayama tea and Baiyu Oolong from Taiwan may be used alone or in combination. It does not matter. When both are used in combination, it is preferable to use approximately equal amounts so that the total content falls within the above range. Of course,
The content is not intended to be limited to this amount, and the content can be appropriately adjusted according to the condition, sex, weight, and the like of the subject within a range in which a desired antibacterial action is obtained.

【0020】また、上記抗菌剤には、本発明の作用を損
なわない範囲で、ビタミンC,ビタミンE,ビタミン
K,葉酸、甘味料、賦型剤、安定化剤等を適宜含有する
ことも可能である。
Further, the above antibacterial agent may appropriately contain vitamin C, vitamin E, vitamin K, folic acid, sweetener, excipient, stabilizer and the like as long as the action of the present invention is not impaired. It is.

【0021】本発明の抗菌剤はブドウ球菌、即ちStaphy
lococcus属に属する細菌、例えばMRSAを含む黄色ブ
ドウ球菌(S. aureus),表皮ブドウ球菌(S. epidermi
dis),腐生ブドウ球菌(S. saprophyticus)等に広く
適用されるが、なかでも特に、MRSAに対し、極めて強力
な抗菌作用を発揮する。
The antibacterial agent of the present invention is Staphylococcus, that is, Staphy
Bacteria belonging to the genus lococcus, for example, S. aureus containing MRSA, S. epidermi
dis) and saprophytic staphylococcus (S. saprophyticus), and among others, exerts an extremely strong antibacterial action on MRSA.

【0022】以下、実施例に基づいてこの発明を詳細に
述べる。ただし、下記実施例はこの発明を制限するもの
ではなく、前・後記の趣旨を逸脱しない範囲で変更実施
することは全てこの発明の技術範囲に包含される。
Hereinafter, the present invention will be described in detail based on embodiments. However, the following embodiments do not limit the present invention, and all modifications and alterations without departing from the spirit of the preceding and following embodiments are included in the technical scope of the present invention.

【0023】[0023]

【実施例】実施例1:種々の台湾産茶及び中国産烏龍茶
を用いたMRSAに対する感受性試験 表1に示す種々の台湾産茶、及び表2に示す種々の中国
産烏龍茶を用い、以下の試験に供した。
EXAMPLES Example 1: Sensitivity test to MRSA using various Taiwanese teas and Chinese oolong tea The following tests were performed using various Taiwanese teas shown in Table 1 and various Chinese oolong teas shown in Table 2. Was served.

【0024】まず、メチシリン耐性黄色ブドウ球菌(M
RSA)を栄養培地内で増殖培養した後、ハロー試験
(Halo test)、即ちペーパーディスク感受性試験に供
した。具体的には、昭和ディスク製直径8mmのディスク
に、表1及び2に示す各濃度の茶を浸み込ませた。各菌
コロニーから釣菌したものを平板培地に塗沫し、その上
に上記ディスクを3個所セットし、37℃のふ卵器で2
4〜48時間培養した後、発育阻止円の幅を測定した。
その結果を表1に示す。
First, methicillin-resistant Staphylococcus aureus (M
RSA) was grown and cultured in a nutrient medium, and then subjected to a halo test, that is, a paper disk sensitivity test. Specifically, a disc having a diameter of 8 mm manufactured by Showa Disc was impregnated with tea of each concentration shown in Tables 1 and 2. What was picked from each bacterial colony was spread on a plate medium, and the above-mentioned three discs were set on the plate medium.
After culturing for 4 to 48 hours, the width of the growth inhibition circle was measured.
Table 1 shows the results.

【0025】[0025]

【表1】 [Table 1]

【0026】[0026]

【表2】 [Table 2]

【0027】これらの結果より、表に示す多種類の台湾
産茶葉及び中国産茶葉のうち、2.5%の極く低濃度濃
度であっても、MRSAに対して優れた抗菌作用を発揮
したのは、白豪烏龍の茶葉及び杉林渓高山茶の茶葉のみ
であることが分かる。
From these results, of the various types of tea leaves from Taiwan and China shown in the table, even at an extremely low concentration of 2.5%, the antibacterial effect was excellent against MRSA. It can be seen that there are only the tea leaves of the white oolong oolong and the tea leaves of Sugirinkei Takayama tea.

【0028】これに対し、他の茶葉については抗菌作用
は殆ど認められず、12.5〜15.0%と、極めて高
濃度に調整した場合にのみ、僅かに抗菌作用を示したに
過ぎなかった。
On the other hand, other tea leaves showed almost no antibacterial effect, and showed only a slight antibacterial effect only when adjusted to an extremely high concentration of 12.5 to 15.0%. Was.

【0029】尚、表には示していないが、MRSA以外
の他のブドウ球菌についても、同様の試験結果が得られ
たことを実験により確認している。
Although not shown in the table, it was confirmed by experiments that similar test results were obtained for staphylococci other than MRSA.

【0030】実施例2:各種菌に対する杉林渓高山茶の
感受性試験 (1)供試菌 供試菌として、メチシリン耐性黄色ブドウ球菌(MRS
A),黄色ブドウ球菌(Staphylococcus aureus野生
株、およびStaphylococcus aureus 209P),表皮ブドウ
球菌(Staphylococcus epidermidis、およびStaphyloco
ccus haemolyticus),腐生ブドウ球菌(Staphylococcu
s saprophyticus)のブドウ球菌;その他に、Streptoco
ccus pneumoniae,Streptococcus agalactiaeの連鎖球
菌;Enterococcus faealisの連鎖腸球菌;更に、Escehr
ichia coli大腸菌,enterohemohemorrhagic E. coli(O
157);Salmonella enteritidis,Salmonella thyphimu
riumなどのサルモネラ菌等合計13菌種を使用した。
Example 2: Susceptibility test of Sugibayashi Takayama tea to various bacteria (1) Test bacteria Methicillin-resistant Staphylococcus aureus (MRS)
A), Staphylococcus aureus (Staphylococcus aureus wild strain and Staphylococcus aureus 209P), Staphylococcus aureus (Staphylococcus epidermidis, and Staphyloco)
ccus haemolyticus), saprophytic staphylococci (Staphylococcu)
s saprophyticus) Staphylococcus; Streptoco
ccus pneumoniae, Streptococcus agalactiae Streptococcus; Enterococcus faealis Streptococcus; and Escehr
ichia coli E. coli, enterohemohemorrhagic E. coli (O
157); Salmonella enteritidis, Salmonella thyphimu
A total of 13 strains such as Salmonella such as rium were used.

【0031】(2)試験方法 上記供試菌を予め、各菌種毎に共通の最適栄養培地内で
増殖培養したこと以外は、前述した実施例1と同様にし
て感受性試験に供した。その結果を表3に示す。
(2) Test method A susceptibility test was performed in the same manner as in Example 1 except that the above test bacteria were grown and cultured in an optimal nutrient medium common to each bacterial species in advance. Table 3 shows the results.

【0032】[0032]

【表3】 [Table 3]

【0033】表3より、杉林渓高山茶の茶葉を用いれ
ば、ブドウ球菌、なかでもMRSAに対して極めて優れ
た抗菌作用を示すことが分かった。同一の茶葉抽出物に
おける抗菌作用を比較すると一目瞭然であるが、ブドウ
球菌の標準株209Pや野生株に対する阻止円幅より
も、MRSAに対する阻止円幅は極めて大きかった。
From Table 3, it was found that the use of the tea leaves of Sugibayashi Takayama tea exhibited an extremely excellent antibacterial effect on staphylococci, especially MRSA. Although the antibacterial activity of the same tea leaf extract is clear at a glance, the inhibition circle for MRSA was much larger than the inhibition circle for staphylococcal standard strain 209P and the wild strain.

【0034】これに対し、ブドウ球菌以外の他の菌種に
ついては抗菌作用は殆ど認められず、高濃度に高めた場
合にのみ、僅かに抗菌作用を示したに過ぎなかった。
On the other hand, antibacterial activity was hardly observed for other strains other than staphylococci, and only when the concentration was increased to a high concentration, the antibacterial activity was only slight.

【0035】尚、参考までに、ブドウ球菌のうちMRS
A、黄色ブドウ球菌(Staphylococcus aureus野生株、
およびStaphylococcus aureus 209P)、並びにO157に対
する阻止円の結果を示す写真を図1に示す。
For reference, MRS among staphylococci
A, Staphylococcus aureus wild strain,
And Staphylococcus aureus 209P), and a photograph showing the results of the inhibition circle for O157 are shown in FIG.

【0036】実施例3:白豪烏龍の各菌種に対する感受
性試験 実施例2において、杉林渓高山茶の代わりに白豪烏龍を
用いたこと以外は実施例2と同様の感受性試験を行っ
た。得られた結果を表4に示す。
Example 3: Susceptibility test for each species of white oolong Oolong The same susceptibility test as in Example 2 was carried out except that white long oolong was used instead of Sugirinkei Takayama tea in Example 2. Was. Table 4 shows the obtained results.

【0037】[0037]

【表4】 [Table 4]

【0038】表4より、白豪烏龍の茶葉を用いた場合に
も、ブドウ球菌に対し、優れた抗菌作用を発揮した。杉
林渓高山茶の場合と同様、MRSAに対する抗菌作用が
極めて強く観察された。
From Table 4, it can be seen that even when the tea leaves of the white oolong oolong were used, an excellent antibacterial action against staphylococci was exhibited. As in the case of Sugibayashi Takayama tea, an extremely strong antibacterial action against MRSA was observed.

【0039】参考までに、ブドウ球菌のうちMRSA、
黄色ブドウ球菌(Staphylococcus aureus野生株、およ
びStaphylococcus aureus 209P)、並びにO157に対する
阻止円の結果を示す写真を図2に示す。
For reference, MRSA among staphylococci,
FIG. 2 shows photographs showing the results of inhibition circles against Staphylococcus aureus (Staphylococcus aureus wild strain and Staphylococcus aureus 209P) and O157.

【0040】実施例4:殺菌効果確認試験(in vitro試
験) 本発明に用いられる杉林渓高山茶及び白豪烏龍が、ブド
ウ球菌に対する殺菌作用を有するか否かを最終的に確認
する目的で、生菌浮遊液に夫々の台湾産茶葉液を加え、
一定時間後に菌が死滅するかどうか調べた。
Example 4: Test for Confirming Bactericidal Effect (In Vitro Test) For the purpose of finally confirming whether Sugibayashi Takayama tea and white oolong dragon used in the present invention have a bactericidal effect against staphylococci. , Add each Taiwanese tea leaf liquor to the viable bacterial suspension,
After a certain period of time, it was examined whether the bacteria were killed.

【0041】詳細には、表3に示す三種の由来株MRS
A浮遊液5ccを容れた各試験管に、杉林渓高山茶葉/
白豪烏龍茶葉の5%溶液を5cc加えた後、37℃のふ
卵器内に24時間放置した後、遠心分離し、沈渣を採取
してスタヒロコッカスNo.110培地に塗抹した。更
に、上記ふ卵器で24時間培養し、コロニーが発生しな
かったときには「−」と判定した。
Specifically, the three types of MRS shown in Table 3
In each test tube containing 5 cc of A suspension, add Sugibayashi Takayama tea leaves /
After adding 5 cc of a 5% solution of white oolong tea leaves, the mixture was allowed to stand in an incubator at 37 ° C. for 24 hours, centrifuged, and the precipitate was collected and spread on Staphylococcus No. 110 medium. Further, the cells were cultured in the above incubator for 24 hours, and when no colony was generated, it was judged as "-".

【0042】得られた結果を表5に併記する。Table 5 also shows the obtained results.

【0043】[0043]

【表5】 [Table 5]

【0044】表5より、台湾産の杉林渓高山茶・白豪烏
龍の茶葉抽出物を添加した場合はいずれも、コロニーの
発生が全く観察されなかったことから、各MRSA菌株
の死滅が確認された。
From Table 5, it was confirmed that the colonies were not observed at all when the tea leaf extract of Sugirinkei Takayama tea and Baigo oolong from Taiwan was added, and that each MRSA strain was killed. Was done.

【0045】実施例5:殺菌効果確認試験(in vivo試
験) 本発明抗菌剤による殺菌作用を更に実証すべく、上記の
in vitro試験に加え、ラットを用いたin vivo試験を行
った。
Example 5: Test for confirming bactericidal effect (in vivo test) In order to further demonstrate the bactericidal action of the antibacterial agent of the present invention,
In addition to the in vitro test, an in vivo test using rats was performed.

【0046】詳細には、SPF由来のSD系成熟健康雄
性ラット合計24匹を4匹/群に分け、表6に示す三種
のMRSA菌浮遊液を5cc/匹ずつラット用ゾンデ針
で直接胃内投与した。投与後30分経過してから、各台
湾産の5.0%茶葉抽出物を5cc/匹ずつ同様に胃内
投与した。24〜48時間経過後、採取した糞便から釣
菌し、スタヒロコッカスNo.110培地に塗抹して37
℃のふ卵器に24〜48時間培養した。発生したコロニ
ーについてはグラム染色を施し、鏡検してブドウ球菌で
あるかどうかを観察した。その結果を表6に併記する。
尚、本実験を行う前に、実験に供したラットの糞便中に
はブドウ球菌は存在していないことを確認している。
In detail, a total of 24 mature SD healthy male rats derived from SPF were divided into 4 rats / group, and the three kinds of MRSA bacteria suspensions shown in Table 6 were directly injected into the stomach at 5 cc / animal using a sonde needle for rats. Was administered. After 30 minutes from the administration, 5.0% tea leaf extract from each Taiwan was similarly intragastrically administered at 5 cc / animal. After 24 to 48 hours, the bacteria were collected from the collected feces and smeared on Staphylococcus No. 110 medium.
The cells were cultured in an incubator at 24 ° C. for 24 to 48 hours. The colonies that developed were stained with Gram and examined microscopically to see if they were Staphylococcus. The results are shown in Table 6.
Before performing this experiment, it was confirmed that staphylococci were not present in the feces of the rats subjected to the experiment.

【0047】[0047]

【表6】 [Table 6]

【0048】表6より、いずれの台湾産の茶葉抽出物に
おいても、コロニーの発生が全く観察されなかったこと
から、各MRSA菌株の死滅が確認された。
From Table 6, no colonies were observed in any of the Taiwanese tea leaf extracts, confirming that each MRSA strain was killed.

【0049】[0049]

【発明の効果】本発明は上記の様に構成されており、ブ
ドウ球菌、特にMRSAに対して、極めて顕著な抗菌作
用を示す抗菌剤を提供することができた。本発明の抗菌
剤は、上述した2種の茶葉/茎から抽出される熱水抽出
液を使用しているので、副作用もなく、安全且つ手軽に
服用できる抗菌剤として極めて有用である。
According to the present invention, an antibacterial agent having a very remarkable antibacterial action against staphylococci, particularly MRSA, can be provided. Since the antibacterial agent of the present invention uses a hot water extract extracted from the above-mentioned two kinds of tea leaves / stalks, it is extremely useful as an antibacterial agent that can be taken safely and easily without side effects.

【図面の簡単な説明】[Brief description of the drawings]

【図1】実施例2において、MRSA、黄色ブドウ球菌
(Staphylococcus aureus野生株、およびStaphylococcu
s aureus 209P)、及びO157に対する阻止円の結果を示
す写真である。
FIG. 1. In Example 2, MRSA, Staphylococcus aureus (Staphylococcus aureus wild strain, and Staphylococcu
21 shows photographs showing the results of inhibition circles for S aureus 209P) and O157.

【図2】実施例3において、MRSA、黄色ブドウ球菌
(Staphylococcus aureus野生株、およびStaphylococcu
s aureus 209P)、及びO157に対する阻止円の結果を示
す写真である。
FIG. 2. In Example 3, MRSA, Staphylococcus aureus (Staphylococcus aureus wild strain, and Staphylococcu
21 shows photographs showing the results of inhibition circles for S aureus 209P) and O157.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】 台湾産の杉林渓高山茶及び/又は白豪烏
龍の茶葉及び/又は茎の熱水抽出物を有効成分として含
有することを特徴とするメチシリン耐性黄色ブドウ球菌
抗菌剤。
1. A methicillin-resistant Staphylococcus aureus antibacterial agent comprising, as an active ingredient, a Taiwanese Sugirinkei Takayama tea and / or a tea extract and / or stem hot water of Bailong Oolong.
JP2001347387A 2000-11-15 2001-11-13 Methicillin-resistant Staphylococcus aureus antibacterial agent Expired - Fee Related JP3746705B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001347387A JP3746705B2 (en) 2000-11-15 2001-11-13 Methicillin-resistant Staphylococcus aureus antibacterial agent

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000348728 2000-11-15
JP2000-348728 2000-11-15
JP2001347387A JP3746705B2 (en) 2000-11-15 2001-11-13 Methicillin-resistant Staphylococcus aureus antibacterial agent

Publications (2)

Publication Number Publication Date
JP2002212090A true JP2002212090A (en) 2002-07-31
JP3746705B2 JP3746705B2 (en) 2006-02-15

Family

ID=26604035

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001347387A Expired - Fee Related JP3746705B2 (en) 2000-11-15 2001-11-13 Methicillin-resistant Staphylococcus aureus antibacterial agent

Country Status (1)

Country Link
JP (1) JP3746705B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010121213A3 (en) * 2009-04-16 2012-08-09 Forsyth Dental Infirmary For Children Antibacterial compositions

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101507533B1 (en) 2014-06-13 2015-04-07 (주)모아캠 Natural preservative composition containing Silver Needle White Tea Extract, Magnolia Obovata Bark Extract and Terminalia Chebula Bark Extract

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010121213A3 (en) * 2009-04-16 2012-08-09 Forsyth Dental Infirmary For Children Antibacterial compositions
US8399220B2 (en) 2009-04-16 2013-03-19 Forsyth Dental Infirmary For Children Antibacterial compositions
US8802105B2 (en) 2009-04-16 2014-08-12 Forsyth Dental Infirmary For Children Antibacterial compositions

Also Published As

Publication number Publication date
JP3746705B2 (en) 2006-02-15

Similar Documents

Publication Publication Date Title
JP5952217B2 (en) Beverage composition
Koech et al. Antioxidant, antimicrobial and synergistic activities of tea polyphenols
Bharath et al. Determination of antibacterial activity of green coffee bean extract on periodontogenic bacteria like Porphyromonas gingivalis, Prevotella intermedia, Fusobacterium nucleatum and Aggregatibacter actinomycetemcomitans: An: in vitro: study
JPH09509677A (en) Antibacterial agent containing tea extract or its active fraction and β-lactam antibiotic
Das et al. Characterization of tea and tea infusion: A study of marketed black tea samples from some tea growing regions of India
Stanley et al. The antibacterial activity of leaf extracts of Ocimum gratissimum and Sida acuta
Singariya et al. Phyto-chemical screening and antimicrobial activities of dhaman grass and Indian Ginseng
Bhargavi et al. An evaluation of the antibacterial activity of root extracts of Manilkara Zapota against Staphylococcus Aureus and Escherichia Coli
Jalil et al. Inhibitory activity of Mentha spicata oils on biofilms of Proteus mirabilis isolated from burns
Canci et al. Antimicrobial potential of aqueous coffee extracts against pathogens and Lactobacillus species: A food matrix application
Parnomo Effect of arabica coffee bean extract (Coffea arabica) as a growth inhibitor of Enterococcus faecalis ATCC 29212
Nozohour et al. Antibacterial activities of ethanolic extract of Malva sylvestris L. against Salmonella enterica and Escherichia coli isolated from diarrheic lambs
Purba et al. Phytochemical screening of bunga rosella (Hibiscus sabdariffa L) and antimicrobial activity test
JP2002212090A (en) Antibacterial agent for methicillin-resistant staphylococcus aureus
CN106554300B (en) Application of the substituted isatin class compound in preparation prevention and/or treatment bacterium infection drug
Aladag et al. Antifungal activity of green tea leaves (Camellia sinensis L.) sampled in different harvest time
Lele et al. Assessment of biological activities of caffeine
Ponmurugan et al. Antibacterial activity of green tea leaves
de Oliveira et al. Effects of Coffea arabica on Streptococcus mutans adherence to dental enamel and dentine
Rahman et al. Antibacterial activity of NESCAFÉ instant coffee beverages and pharyngitis-causing Streptococcus species
US20020098248A1 (en) Method for treating and/or preventing infections caused by methicillin-resistant Staphylococcus aureus
KR20190136199A (en) Drink composition comprising Moringa-fermentation product
Chouhan et al. Studies onantibacterial potential of asparagus racemosus extract against bacteria causing UTI
Hindi et al. Effectiveness of Aqueous extract of Green, Black and Red Tea Leaves against some types of Gram positive and negative bacteria
CN111135182B (en) Antibacterial product and preparation method and application thereof

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041014

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20051115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20051124

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091202

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101202

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101202

Year of fee payment: 5

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101202

Year of fee payment: 5

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20111202

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121202

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131202

Year of fee payment: 8

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees
R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370